Effect of the Antihypertensive Drug Enalapril on Oxidative Stress Markers and Antioxidant Enzymes in Kidney of Spontaneously Hypertensive Rat
暂无分享,去创建一个
M. Swamy | K. Sirajudeen | G. Chandran | M. Samarendra | Nik Rizal Nik Yusoff | Kuttulebbai N. S. Sirajudeen | Mummedy Swamy
[1] W. Marsden. I and J , 2012 .
[2] H. Singh,et al. Glutathione system in young spontaneously hypertensive rats , 2010, Journal of Physiology and Biochemistry.
[3] H. Khanna,et al. Oxidative stress in hypertension: association with antihypertensive treatment. , 2008, Indian journal of physiology and pharmacology.
[4] N. Vaziri. Causal link between oxidative stress, inflammation, and hypertension. , 2008, Iranian journal of kidney diseases.
[5] E. Frohlich,et al. Analogy of cardiac and renal complications in essential hypertension and aged SHR or L-NAME/SHR. , 2007, Medicinal chemistry (Shariqah (United Arab Emirates)).
[6] A. Mimran,et al. Prevention and Reversal by Enalapril of Target Organ Damage in Angiotensin II Hypertension , 2005, Journal of the renin-angiotensin-aldosterone system : JRAAS.
[7] S. Meng,et al. Oxidative Stress and Antioxidant Treatment in Hypertension and the Associated Renal Damage , 2005, American Journal of Nephrology.
[8] M. Hughson,et al. Antioxidant Treatment Prevents Renal Damage and Dysfunction and Reduces Arterial Pressure in Salt-Sensitive Hypertension , 2005, Hypertension.
[9] C. Mandarim-de-Lacerda,et al. Kidney adaptation in nitric oxide-deficient Wistar and spontaneously hypertensive rats. , 2004, Life sciences.
[10] G. Remuzzi,et al. ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? , 2004, Journal of the American Society of Nephrology : JASN.
[11] T. Berl. Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: the case for AT1 receptor antagonist. , 2004, Journal of the American Society of Nephrology : JASN.
[12] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[13] J. Boffa,et al. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. , 2003, Journal of the American Society of Nephrology : JASN.
[14] D. Eatman,et al. Effect of losartan on oxidative stress-induced hypertension in Sprague-Dawley rats. , 2001, American journal of hypertension.
[15] C. Patrono,et al. Increased Oxidative Stress and Platelet Activation in Patients With Hypertension and Renovascular Disease , 2002, Circulation.
[16] D. Eatman,et al. Effect of palm oil on oxidative stress-induced hypertension in Sprague-Dawley rats. , 2002, American journal of hypertension.
[17] C. Wilcox. Reactive oxygen species: Roles in blood pressure and kidney function , 2002, Current hypertension reports.
[18] Kevin Barraclough,et al. I and i , 2001, BMJ : British Medical Journal.
[19] D. Harrison,et al. Oxidative stress and vascular damage in hypertension , 2001, Coronary artery disease.
[20] G. Koraćević,et al. Method for the measurement of antioxidant activity in human fluids , 2001, Journal of clinical pathology.
[21] R. M. Lee,et al. Abnormal renal medullary response to angiotensin II in SHR is corrected by long-term enalapril treatment. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.
[22] R. Zatz,et al. Mycophenolate Mofetil Reduces Renal Injury in the Chronic Nitric Oxide Synthase Inhibition Model , 2001, Hypertension.
[23] D. O'Connor,et al. Plasma Hydrogen Peroxide Production in Human Essential Hypertension: Role of Heredity, Gender, and Ethnicity , 2000, Hypertension.
[24] V. Preedy,et al. Effects of lisinopril and amlodipine on antioxidant status in experimental hypertension. , 2000, Clinica chimica acta; international journal of clinical chemistry.
[25] S. Cuzzocrea,et al. Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat. , 2000, Kidney international.
[26] L. Rybak,et al. Dose response of ethanol on antioxidant defense system of liver, lung, and kidney in rat. , 2000, Pathophysiology : the official journal of the International Society for Pathophysiology.
[27] M. Gerová. Nitric oxide-compromised hypertension: facts and enigmas. , 2000, Physiological research.
[28] L. Rosenfeld,et al. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.
[29] J. Himberg,et al. Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension. , 1998, Hypertension.
[30] D. Girelli,et al. Anti‐oxidant status and lipid peroxidation in patients with essential hypertension , 1998, Journal of hypertension.
[31] Y. Pinto,et al. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. , 1998, Cardiovascular research.
[32] R. M. Lee,et al. Blood pressure and heart rate development in young spontaneously hypertensive rats. , 1998, American journal of physiology. Heart and circulatory physiology.
[33] W. Linz,et al. Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. , 1997, Hypertension.
[34] G. Macdonald,et al. NITRIC OXIDE SYNTHASE INHIBITION IN A SPONTANEOUSLY HYPERTENSIVE RAT MODEL OF DIABETIC NEPHROPATHY , 1997, Clinical and experimental pharmacology & physiology.
[35] D. Harrison,et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.
[36] S. Maxwell,et al. Antioxidant status in controlled and uncontrolled hypertension and its relationship to endothelial damage. , 1994, Journal of human hypertension.
[37] K. Köse,et al. Oxidative enzymes of polymorphonuclear leucocytes and plasma fibrinogen, ceruloplasmin, and copper levels in Behçet's disease. , 1994, Clinical biochemistry.
[38] J. Swales. Textbook of hypertension , 1994 .
[39] J. McCord. Human disease, free radicals, and the oxidant/antioxidant balance. , 1993, Clinical biochemistry.
[40] A. Deng,et al. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. , 1992, The Journal of clinical investigation.
[41] C. Cross,et al. Free radicals, antioxidants, and human disease: where are we now? , 1992, The Journal of laboratory and clinical medicine.
[42] W. Weglicki,et al. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. , 1992, Circulation research.
[43] L. Góth,et al. A simple method for determination of serum catalase activity and revision of reference range. , 1991, Clinica chimica acta; international journal of clinical chemistry.
[44] J. Lunec. Free Radicals: Their Involvement in Disease Processes , 1990, Annals of clinical biochemistry.
[45] M. Yamanaka,et al. Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. , 1986, Clinical chemistry.
[46] R. Stephenson. A and V , 1962, The British journal of ophthalmology.
[47] M. DePamphilis,et al. HUMAN DISEASE , 1957, The Ulster Medical Journal.
[48] S. S.,et al. Free Radicals , 1933, Nature.